Is a diabetes pay-for-performance program cost-effective under the National Health Insurance in Taiwan?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In October 2001, a pay-for-performance (P4P) program for diabetes was implemented by the National Health Insurance (NHI), a single-payer program, in Taiwan. However, only limited information is available regarding the influence of this program on the patient’s health-related quality of life. The aim of this study was to estimate the costs and consequences of enrolling patients in the P4P program from a single-payer perspective.
A retrospective observational study of 529 diabetic patients was conducted between 2004 and 2005. The data used in the study were obtained from the National Health Interview Survey (NHIS) in Taiwan. Direct cost data were obtained from NHI claims data, which were linked to respondents in the NHIS using scrambled individual identification. The generic SF36 health instrument was employed to measure the quality-of-life-related health status and transformed into a utility index. Patients enrolled in the P4P program for at least 3 months were categorized as the P4P group. Following propensity score matching, 260 patients were included in the study. Outcomes included life-years, quality-adjusted life-years (QALYs), diabetes-related medical costs, overall medical costs, and incremental cost-effectiveness ratios (ICERs). A single-payer perspective was assumed, and costs were expressed in US dollars. Nonparametric bootstrapping was conducted to estimate confidence intervals for cost-effectiveness ratios.
Following matching, no significant difference was noted between two groups with regard to the patients’ age, gender, education, family income, smoking status, BMI, or whether insulin was used. The P4P group had an increase of 0.08 (95 % CI 0.077–0.080) in QALYs, and the additional diabetes-related medical cost was US$422.74 (95 % CI US$413.58–US$435.05), yielding an ICER of US$5413.93 (95 % CI US$5226.83–US$5562.97) per QALY gained.
Our results provides decision makers with valuable information regarding the impact of the P4P program of diabetes care through a direct comparison of equivalent groups of patients receiving regular care. Under the single-payer NHI system, the use of financial incentives under the DM-P4P program may be an effective means to ensure the quality of follow-up treatment.
- Institute of Medicine. (2001). Crossing the Quality Chasm: A new Health System for the 21st Century. Washington, DC: National Academies Press.
- Chen, J. Y., Tian, H., Taira Juarez, D., Hodges, K. A., Brand, J. C., Chung, R. S., et al. (2010). The effect of a PPO pay-for-performance program on patients with diabetes. American Journal of Managed Care, 16(1), e11–e19.
- Lee, T. T., Cheng, S. H., Chen, C. C., & Lai, M. S. (2010). A pay-for-performance program for diabetes care in Taiwan: A preliminary assessment. American Journal of Managed Care, 16(1), 65–69.
- Levin-Scherz, J., DeVita, N., & Timbie, J. (2006). Impact of pay-for-performance contracts and network registry on diabetes and asthma HEDIS measures in an integrated delivery network. Medical Care Research and Review, 63(1 Suppl), 14S–28S. CrossRef
- Tahrani, A. A., McCarthy, M., Godson, J., Taylor, S., Slater, H., Capps, N., et al. (2007). Diabetes care and the new GMS contract: The evidence for a whole county. British Journal of General Practice, 57(539), 483–485.
- Campbell, S. M., Reeves, D., Kontopantelis, E., Sibbald, B., & Roland, M. (2009). Effects of pay for performance on the quality of primary care in England. New England Journal of Medicine, 361(4), 368–378. CrossRef
- Vaghela, P., Ashworth, M., Schofield, P., & Gulliford, M. C. (2009). Population intermediate outcomes of diabetes under pay-for-performance incentives in England from 2004 to 2008. Diabetes Care, 32(3), 427–429. CrossRef
- Hillman, A. L., Ripley, K., Goldfarb, N., Nuamah, I., Weiner, J., & Lusk, E. (1998). Physician financial incentives and feedback: Failure to increase cancer screening in Medicaid managed care. American Journal of Public Health, 88(11), 1699–1701. CrossRef
- Glickman, S. W., Ou, F. S., DeLong, E. R., Roe, M. T., Lytle, B. L., Mulgund, J., et al. (2007). Pay for performance, quality of care, and outcomes in acute myocardial infarction. JAMA, 297(21), 2373–2380. CrossRef
- Fagan, P. J., Schuster, A. B., Boyd, C., Marsteller, J. A., Griswold, M., Murphy, S. M. E., et al. (2010). Chronic care improvement in primary care: Evaluation of an integrated pay-for-performance and practice-based care coordination program among elderly patients with diabetes. Health Services Research, 45(6), 1763–1782. CrossRef
- Department of Health, E. Y., R.O.C. (Taiwan) (2010). 2009 Statistic of Cause of Death. Taipei City.
- Bureau of National Health Insurance, D. o. H., Executive Yuan, R.O.C. (Taiwan). (2010). The 2009 National Health Insurance Annual Health Statistical Report. Taipei City.
- Chiou, S. T., Lin, H. D., Yu, N. C., Hseuh, H. K., Lin, L. H., Lin, L. T., et al. (2001). An initial assessment of the feasibility and effectiveness of implementing diabetes shared care system in Taiwan—some experiences from I-Lan County. Diabetes Research and Clinical Practice, 54(Suppl 1), S67–S73. CrossRef
- Bureau of National Health Insurance. National Health Insurance Pay-for-Performance Program for Diabetes [in Chinese]. Retrieved June 20, 2011, from http://www.nhi.gov.tw/webdata/webdata.aspx?menu=18&menu_id=703&webdata_id=3862&WD_ID=941.
- Lee, T–. T., Cheng, S.-H., Chen, C–. C., & Lai, M.-S. (2010). A pay-for-performance program for diabetes care in Taiwan: A preliminary assessment. American Journal of Managed Care, 16(1), 65–69.
- Cheng, S. H., Lee, T. T., & Chen, C. C. (2012). A longitudinal examination of a pay-for-performance program for diabetes care evidence from a natural experiment. Medical Care, 50(2), 109–116. CrossRef
- Chen, P. C., Lee, Y. C., & Kuo, R. N. (2012). Differences in patient reports on the quality of care in a diabetes pay-for-performance program between 1 year enrolled and newly enrolled patients. International Journal for Quality in Health Care, 24(2), 189–196. CrossRef
- Gold, M. R., Sigegl, J. E., Russell, L. B., & Weinstein, M. C. (1996). Cost Effectiveness in Health and Medicine. New York: Oxford University Press.
- Krummenauer, F., Wolf, C., Gunther, K. P., & Kirschner, S. (2009). Clinical benefit and cost effectiveness of total knee arthroplasty in the older patient. European Journal of Medical Research, 14(2), 76–84. CrossRef
- Pollock, R. F., Muduma, G., & Valentine, W. J. (2013). Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK. Diabetes, Obesity and Metabolism, 15(2), 121–129. CrossRef
- Weng, W. S., Liu, C. Y., Chen, Y. J., Chang, H. Y., Liang, K. Y., & Chuang, Y. L. (2006). The sampling design for the 2005 National Health Interview Survey in Taiwan. NHIS Research Brief, 2, 1–16. CrossRef
- Li, C. L., Chang, H. Y., Wang, H. H., & Bai, Y. B. (2011). Diabetes, functional ability, and self-rated health independently predict hospital admission within one year among older adults: A population based cohort study. Archives of Gerontology and Geriatrics, 52(2), 147–152. CrossRef
- National Health Research Institute. National Health Interview Survey. Retrieved June 16, 2011, from http://nhis.nhri.org.tw/2005nhis.html.
- Chang, W. C., Lan, T. H., Ho, W. C., & Lan, T. Y. (2010). Factors affecting the use of health examinations by the elderly in Taiwan. Archives of Gerontology and Geriatrics, 50(Suppl 1), S11–S16. CrossRef
- Wu, M. S., Lan, T. H., Chen, C. M., Chiu, H. C., & Lan, T. Y. (2011). Socio-demographic and health-related factors associated with cognitive impairment in the elderly in Taiwan. BMC Public Health, 11, 22. CrossRef
- Wu, W. C., Chang, H. Y., Kuo, K. N., Chen, C. Y., Tu, Y. C., & Yang, Y. H. (2011). Psychosocial problems in children with allergic diseases: A population study in Taiwan. Child: Care, Health and Development, 37, 662.
- Lin, C. C., Lai, M. S., Syu, C. Y., Chang, S. C., & Tseng, F. Y. (2005). Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. Journal of the Formosan Medical Association, 104(3), 157–163.
- Miller, C. K., Kristeller, J. L., Headings, A., Nagaraja, H., & Miser, W. F. (2012). Comparative effectiveness of a mindful eating intervention to a diabetes self-management intervention among adults with type 2 diabetes: A pilot study. Journal of the Academy of Nutrition and Dietetics, 112(11), 1835–1842. CrossRef
- Rosenbaum, P. R., & Rubin, D. B. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70(1), 41–55. CrossRef
- D’Agostino, R. B. (1998). Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statistics in Medicine, 17(19), 2265–2281. CrossRef
- Knox, S. (2013). Sample size calculation in economic evaluation. Australia: The Centre for Health Economic Research and Evaluation (CHERE).
- Glick, H. A. (2011). Sample size and power for cost-effectiveness analysis (Part 1). Pharmacoeconomics, 29(3), 189–198. CrossRef
- Glick, H. A. (2011). Sample size and power for cost-effectiveness analysis (Part 2) the effect of maximum willingness to pay. Pharmacoeconomics, 29(4), 287–296.
- Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 21(2), 271–292. CrossRef
- McCabe, C., Brazier, J., Gilks, P., Tsuchiya, A., Roberts, J., O’Hagan, A., et al. (2006). Using rank data to estimate health state utility models. Journal of Health Economics, 25(3), 418–431. CrossRef
- Kharroubi, S. A., Brazier, J. E., Roberts, J., & O’Hagan, A. (2007). Modelling SF-6D health state preference data using a nonparametric Bayesian method. Journal of Health Economics, 26(3), 597–612. CrossRef
- Polsky, D., Glick, H. A., Willke, R., & Schulman, K. (1997). Confidence intervals for cost-effectiveness ratios: A comparison of four methods. Health Economics, 6(3), 243–252. CrossRef
- Fenwick, E., Marshall, D. A., Levy, A. R., & Nichol, G. (2006). Using and interpreting cost-effectiveness acceptability curves: An example using data from a trial of management strategies for atrial fibrillation. Bmc Health Services Research, 6, 52. CrossRef
- Devlin, N., & Parkin, D. (2004). Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics, 13(5), 437–452. CrossRef
- George, B., Harris, A., & Mitchell, A. (2001). Cost effectiveness analysis and the consistency of decision making––Evidence from pharmaceutical reimbursement in Australia (1991–1996). Pharmacoeconomics, 19(11), 1103–1109. CrossRef
- Bridges, J. F. P., Onukwugha, E., & Mullins, C. D. (2010). Healthcare rationing by proxy cost-effectiveness analysis and the misuse of the $50 000 threshold in the US. Pharmacoeconomics, 28(3), 175–184. CrossRef
- Oluwatowoju, I., Abu, E., Wild, S. H., & Byrne, C. D. (2010). Improvements in glycaemic control and cholesterol concentrations associated with the quality and outcomes framework: A regional 2-year audit of diabetes care in the UK. Diabetic Medicine, 27(3), 354–359. CrossRef
- Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine, 359(15), 1577–1589. CrossRef
- Curtin, K., Beckman, H., Pankow, G., Milillo, Y., & Green, R. A. (2006). Return on investment in pay for performance: A diabetes case study. Journal of Healthcare Management, 51(6), 365–374.
- Chen, T. T., Chung, K. P., Lin, I. C., & Lai, M. S. (2011). The unintended consequence of diabetes mellitus pay-for-performance (P4P) program in Taiwan: Are patients with more comorbidities or more severe conditions likely to be excluded from the P4P program? Health Services Research, 46(1 Pt 1), 47–60. CrossRef
- Solli, O., Stavem, K., & Kristiansen, I. S. (2010). Health-related quality of life in diabetes: The associations of complications with EQ-5D scores. Health and Quality of Life Outcomes, 8(18), 1–8.
- Winkelmayer, W. C., & Kurth, T. (2004). Propensity scores: Help or hype? Nephrology, Dialysis, Transplantation, 19(7), 1671–1673. CrossRef
- Is a diabetes pay-for-performance program cost-effective under the National Health Insurance in Taiwan?
Quality of Life Research
Volume 23, Issue 2 , pp 687-696
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Diabetes mellitus
- Incremental cost-effectiveness ratio
- Industry Sectors
- Author Affiliations
- 1. Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan
- 2. Center for Drug Evaluation, Taipei, Taiwan
- 3. School of Health Care Administration, Taipei Medical University, Taipei, Taiwan